louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06256679: RADIOFREQUENCY TREATMENT OF CHRONIC PELVIC PAIN MANAGEMENT IN INTERSTITIAL CYSTITIS
Official title: SUPERIOR HYPOGASTRIC PLEXUS PULSED RADIOFREQUENCY COMBINED WITH POSTERIOR TIBIALIS NERVE TRANSCUTANEOUS RADIOFREQUENCY AS A TREATMENT OPTION OF CHRONIC PELVIC PAIN MANAGEMENT IN INTERSTITIAL CYSTITIS
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Cystitis, Chronic
Lead sponsor: Turkish League Against Rheumatism
Sponsor class: OTHER
First posted: 2024-02-13
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 34 patients diagnosed with interstitial cystitis by the urology department and experiencing symptoms for at least 3 months, who had undergone superior hypogastric nerve pulsed radiofrequency by our team, were retrospectively included in the study at the Algology Clinic of Hacettepe University Faculty of Medicine. Some of these patients had also undergone transcutaneous posterior tibial nerve stimulation.

Brief summary: Interstitial cystitis/painful bladder syndrome is a collection of symptoms that includes urinary urgency, urge incontinence, nocturia, and painful urination. Various treatment modalities are utilized in the management of the disease. Superior hypogastric plexus block, which is used in the treatment of chronic pelvic pain, is one of these treatment methods. Additionally, tibial nerve stimulation is used in the treatment of urinary symptoms. This study aims to compare the effectiveness of superior hypogastric plexus pulsed radiofrequency and adjunctive transcutaneous tibial nerve stimulation in the treatment of patients with interstitial cystitis


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-65 years
* Diagnosed with interstitial cystitis and experiencing symptoms for at least 3 months

Exclusion Criteria:

* Pregnancy or breastfeeding
* Patients with renal, hepatic, cardiovascular, or psychiatric diseases
* Additional interventional treatments within the first 3 months after the procedure
* A history of previous surgery or trauma

Primary outcomes:
measure: Numerical Rating Scale (NRS)
timeFrame: Pre-intervention, 1st month, 3rd month
measure: Neuropathic Pain 4 Questions (DN4)
timeFrame: Pre-intervention, 1st month, 3rd month
measure: The O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)
timeFrame: Pre-intervention, 1st month, 3rd month
measure: Interstitial Cystitis Problem Index (ICPI)
timeFrame: Pre-intervention, 1st month, 3rd month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University Faculty of Medicine
Study officials:
References:
Clinical trial NCT01820884: The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
Official title: The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Endometrial Neoplasms
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Shandong University
name: Huazhong University of Science and Technology
name: Zhejiang University
First posted: 2013-03-29
Enrollment: 240
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized trial is studying the efficacy and safety of the hysterectomy alone compared with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA endometrial carcinoma.


Eligibility criteria: Inclusion Criteria:

* FIGO stage: ⅠA, endometrial carcinoma;
* Female, Chinese women;
* premenopausal women；
* ≤ 50 years old;
* Pathological diagnosis by curettage/hysteroscopy : G1
* No prior treatment;
* Provide written informed consent.

Exclusion Criteria:

* The suspicious metastasis of ovarian;
* Family history of ovarian cancer;
* Suffering from other malignancies;
* Concurrently participating in other clinical trials;
* Unable or unwilling to sign informed consents;
* Unable or unwilling to abide by protocol.

Primary outcomes:
measure: Disease-free survival (DFS)
timeFrame: 3-year DFS
Secondary outcomes:
measure: Clinical gynecologic endocrine function
timeFrame: 1-year period
measure: Quality of Life
timeFrame: 3-year period
measure: Overall Survival (OS)
timeFrame: 3-year OS
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
city: Jinan
country: China
facility: Qilu Hospital，Shandong University
state: Shandong
city: Hangzhou
country: China
facility: Women's Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
affiliation: Shandong University
name: Beihua Kong, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06792084: The Effect of Motivational Interviewing on Ethical Decision Making and Moral Distress
Official title: The Effect of Motivational Interviewing on Ethical Decision Making and Moral Distress Levels in Intensive Care Nurses: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Ethics
Moral Distress
Keywords: ethics
moral distress
intensive care nurses
Lead sponsor: Nevsehir Haci Bektas Veli University
Sponsor class: OTHER
First posted: 2025-01-24
Enrollment: 54
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: It is a pretest-posttest, randomized controlled experimental study with a control group.
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is a pre-test-post-test, randomized controlled experimental study with a control group, planned to examine the effect of motivational interviewing on ethical decision-making and moral distress levels in intensive care nurses.

Detailed description: The research was designed individually. The research will be conducted between 30 JANUARY 2025 and 27 FEBRUARY 2025, with Certificates working in the intensive care units of the Cumhuriyet University Faculty of Medicine in Sivas-Central province of Turkey and meeting the included criteria. The study will be carried out face to face after obtaining the necessary institutional permissions. At each stage of the research, the quantities will be taken into consideration, taking into account the inclusion criteria. They will be asked to fill out informed consent forms asking to explain the subject, purpose and method of receiving the study. Participants will be divided into intervention and control groups by simple randomization method. Participant Information Form, Ethical Dilemma Test in Nursing and Moral Distress Scale will be applied to both groups before the intervention. Data collection tools will be applied to the control group simultaneously with the intervention group. The picture of the implementation of the study will be recorded by the hospital management where appropriate and will be carried out in a private area. At the end of the intervention program, the Nursing Ethical Dilemma Test and Moral Distress Scale will be administered to both groups.

Eligibility criteria: Inclusion Criteria:

* Nurses working in Intensive Care Clinics who volunteer to participate in the study will be included.

Exclusion Criteria:

* Being diagnosed with any mental illness

Primary outcomes:
measure: Ethical decision making
timeFrame: 5 week
Secondary outcomes:
measure: Moral Distress
timeFrame: 5 week
Other outcomes:
Locations:
city: Si̇vas
country: Turkey
facility: Cumhuriyet University Medical Faculty Hospital
state: Center
Study officials:
affiliation: Nevsehir Haci Bektas Veli University
name: SEMRA SEYHAN ŞAHİN, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00559884: A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects
Official title: An Open-label, Randomized, Single Dose, Crossover Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Modified Release Formulations of GSK189075 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Keywords: pharmacokinetics,
healthy male and females,
pharmacodynamics
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-11-16
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to look at concentrations of GSK189075 in blood when different long and short acting forms of the drug are taken by mouth. The results will help to decide whether a long-acting form of GSK189075 can be made. The effects of the drug on the body and safety will also be studied.


Eligibility criteria: Inclusion Criteria:

* Are a healthy, non-smoking adult, 18 to 55 years old.
* Are not overly thin or overly heavy for your height.
* Are a female who is unable to have children, or is willing to use birth control throughout the study.
* Are willing and able to follow all study-related instructions provided by the site staff. - Are willing to provide signed consent.

Exclusion Criteria:

* Are a pregnant or a nursing female.
* Have a past or current disease such as heart, liver, kidney, blood, brain, or other disease.
* Have had certain infections within 4 weeks before the expected the first dose of study drug.
* Have HIV or hepatitis, or have alcohol in your system at the screening visit.
* Have a history of alcohol abuse.
* Have been in another research study in the last month or have taken certain medications in the 2 weeks before study drug would be taken.
* Have laboratory tests that are outside the normal range.

Primary outcomes:
measure: Blood samples:
timeFrame: collected over 24-hour period after each different form of GSK189075 given to measure amount of drug in blood
measure: Urine:
timeFrame: collected over 24-hour period after dosing with each form to measure amount of urine produced & amount of sugar in urine
Secondary outcomes:
measure: Adverse events:
timeFrame: all visits after Day -1
measure: blood pressure & heart rate:
timeFrame: screening,Day -1 - Day 1,follow-up visit
measure: ECGs:
timeFrame: screening,pre-dose, Day 1
measure: lab tests:
timeFrame: screening, Day -1 - Day 1,follow-up
Other outcomes:
Locations:
city: Columbus
country: United States
facility: GSK Investigational Site
state: Ohio
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT05754684: Quadruple Immunotherapy for Neuroblastoma
Official title: Quadruple Immunotherapy for Paediatric Patients with Relapsed or Refractory Neuroblastoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Neuroblastoma Recurrent
Lead sponsor: Hong Kong Children's Hospital
Sponsor class: OTHER
Collaborators: name: The University of Hong Kong
First posted: 2023-03-06
Enrollment: 29
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.

Detailed description: Included patients will receive intravenous infusion of donor NK cells on day 0, and anti-GD2 antibody (dinutuximab) on day -6 to day -2. IL-2 will be given subcutaneously on day -1, day +1, day +3, day +5, day +7, and day +9. Subcutaneous injection of GM-CSF will be started on day 0, given daily till neutrophil count \>1000/mm3. Spironolactone will be started orally on day -1, given three times daily till cessation of GM-CSF.

Alternative anti-GD2 antibody (Naxitamab) can be used instead of dinutuximab, to be given on day -5, day -3, day +1 and day +3.

Eligibility criteria: Inclusion Criteria:

* relapsed or refractory neuroblastoma
* Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
* Karnofsky or Lansky performance status score ≥50
* Has an appropriate HLA-haploidentical NK-cell donor available

Exclusion Criteria:

* Pregnant or lactating woman
* HIV infection
* Patients for whom conventional treatment is deemed more appropriate
* Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \<1 month

Primary outcomes:
measure: Proportion of patients who have objective response in the tumor
timeFrame: 1-2 months
Secondary outcomes:
measure: Overall survival at 1 year
timeFrame: up to 1 year
measure: Progression-free survival
timeFrame: up to 1 year
measure: Proportion of patients who have tumor relapse
timeFrame: up to 1 year
measure: Number of patients who experience adverse events
timeFrame: up to 1 month
measure: Percentage of donor NK cells
timeFrame: up to 1 year
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Hong Kong Children&#39;s Hospital
Study officials:
affiliation: Hong Kong Children's Hospital
name: Daniel Cheuk
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06773884: Population-based Registry Study on Primary Hip Fracture Surgery
Official title: Population-based Registry Study on Primary Hip Fracture Surgery
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Hip Fracture
Keywords: Hip Fracture
Primary Hip Fracture Surgery
Perioperative Risk Factors
Reoperation Rates
Mortality
Geriatric Fractures
Epidemiology
Swedish Perioperative Registry (SPOR)
Population-Based Study
Lead sponsor: Region Örebro County
Sponsor class: OTHER
Collaborators: name: Stockholm South General Hospital
First posted: 2025-01-14
Enrollment: 90000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 18 years and older who underwent hip fracture surgery and were recorded in SPOR from January 1, 2018, to December 31, 2022.

Brief summary: This study aims to describe primary hip fracture surgeries and to identify patient-related and perioperative risk factors affecting outcomes. It will utilize data from the Swedish Perioperative Registry (SPOR) and the Swedish National Patient Register to track epidemiological changes, treatment outcomes, and perioperative factors.

Detailed description: Hip fractures, a significant health concern among the elderly, necessitate hospitalization and surgical intervention, with high mortality and morbidity rates within the first year post-surgery. The study will retrospectively analyze records of approximately 90,000 patients over 18 who underwent hip fracture surgery between 2018 and 2022. Key factors such as age, sex, preoperative health status, and perioperative care methods will be evaluated to determine their impact on complications, reoperation rates, and survival.

This research could inform future clinical practices and policies, aiming to optimize the treatment and management of elderly patients with hip fractures.

Eligibility criteria: Inclusion Criteria:

- Patients aged 18+ with hip fractures, identified through ICD code S72\*, who underwent surgery during the study period.

Exclusion Criteria:

* Patients without a Swedish personal identification number, as this is necessary to link data across registers.

Primary outcomes:
measure: Rate of reoperation and secondary fractures.
timeFrame: One year post-surgery
Secondary outcomes:
measure: Mortality rate, hospitalization duration, and time to surgery
timeFrame: One year post-surgery
Other outcomes:
Locations:
city: Örebro
country: Sweden
facility: Universitetsjukhuset
Study officials:
References:
Clinical trial NCT05728684: Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
Official title: A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: IgG4 Related Disease
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2023-02-15
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Detailed description: This study includes three stages: screening period, treatment period and safety follow-up period.

Eligibility criteria: Inclusion Criteria:

* ≥18 years, male and female.
* With IGG4-related disease.

Exclusion Criteria:

* Inoculate live vaccine within 4 weeks before screening.
* Treponema pallidum antibody positive in screening period.
* Active hepatitis in screening period.
* With a history of solid organ or cell transplantation within 6 months before screening.
* With other medical or non-medical conditions that are not suitable for the study by the investigator.

Primary outcomes:
measure: Response rate
timeFrame: up to week 12
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01150084: "Step by Step": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees
Official title: "Step by Step": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Exercise
Sedentary
Keywords: increasing physical activity in sedentary employees
Lead sponsor: University of Birmingham
Sponsor class: OTHER
Collaborators: name: BUPA Foundation
First posted: 2010-06-24
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Increasing rates of sedentary living, often complemented by obesity, among large segments of the adult population are associated with costs to individual health and well-being and thereby to society as a whole. Although some workplaces offer physical activity opportunities, those employees who tend to need it the most (i.e., the health needy) are often not attracted. In this project, the investigators propose to develop and evaluate a programme that is targeted to the sedentary health needy employees. The investigators will work with the corporate partner (a large university) to attract such employees through an extensive social marketing driven campaign. A 16-week lunchtime walking programme is proposed in which walking groups are offered followed by support and motivational strategies for longer term independent walking. The investigators will examine the effects of the programme on total amount of walking (including a follow-up assessment 4 months later) and will use innovative technology (Smartphones) to also examine the effect of lunchtime walks on well-being and work performance within and between participants.


Eligibility criteria: Inclusion Criteria:

* healthy, mobile, 18-65 year old employees who report they are engaging in less than 30 minutes of moderate intensity physical activity per week

Exclusion Criteria:

* employees with significant auditory or visual problems and those who have severe musculoskeletal disorders that prevent them from engaging in physical activity. Medical clearance will be requested for those who report any cardiovascular disease.

Primary outcomes:
measure: number of steps
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: University of Birmingham
state: West Midlands
Study officials:
affiliation: University of Birmingham
name: Cecilie Thogersen-Ntoumani, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02765984: Relation of Implantation Site to Placental Site
Official title: Relation of Implantation Site to Placental Site With or Without Cesarean Section Scar
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Placenta Implantation Site
Keywords: implantation site
placental site
Doppler
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2016-05-09
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnant women at their early trimester with or without cesarean section scar

Brief summary: Trans vaginal ultrasound with a partially full bladder will be done at gestational age earlier than 10 weeks to assess the site of intrauterine gestational sac to the endometrial cavity and the distance between the implantation site and the internal cervical os . Doppler assessment of the retrochorionic blood flow at the area behind the maximum chorionic tissue to detect resistance index.


Eligibility criteria: Inclusion Criteria:

* Single intrauterine pregnancy
* Gestational age less than 10 weeks

Exclusion Criteria:

* Any condition distorting uterine cavity as myoma, uterine anomalies.
* Absent fetal pulsations
* Any condition needing termination of early pregnancy as molar pregnancy or severe deteriorating maternal disease

Primary outcomes:
measure: Distance between the implantation site and the internal cervical os
timeFrame: 10 weeks to 40 weeks gestational age
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmed Maged
Study officials:
affiliation: Cairo University
name: Ahmed Maged, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05401084: Diet in the Management of Acromegaly
Official title: Impact of Low Carbohydrate and Low Gluten Diet on Acromegaly Progression, Symptoms, Complications, and Treatment Outcomes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acromegaly
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
First posted: 2022-06-02
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Impact of low carbohydrate and low gluten diet on acromegaly progression, symptoms, complications, and treatment outcomes.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of acromegaly.

Exclusion Criteria:

* Diet restrictions.

Primary outcomes:
measure: Change in insulin-like growth factor 1 (IGF-1).
timeFrame: 8 weeks
measure: Change in growth hormone level (GH).
timeFrame: 8 weeks
measure: Change in acromegaly related symptoms.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
Study officials:
References: